Good morning :)
$
₹
Novartis AG ADR

Novartis AG ADR

NVS

NYSE
Asset Logo

Novartis AG ADR

NVS

NYSE
$161.911.85% (-3.06)
$
₹
$161.911.85% (-3.06)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mega Cap

With a market cap of $300.8B the stock is ranked 42

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

30.39
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

8.19
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$5.24
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

3.85
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

17.49%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

2.98%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 12 analysts reports

Buy
5 analysts
Hold
5 analysts
Sell
2 analysts

Price Upside

-4.4%

Earnings Growth

+2.01%

Rev. Growth

+4.69%

See Detailed Forecast

Company Profile

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.78
45.78
1Y Return
47.62%
47.62%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.39
40.39
1Y Return
47.33%
47.33%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
149.14
149.14
1Y Return
74.12%
74.12%
Buy Reco %
67.85
67.85
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.00
26.00
1Y Return
14.37%
14.37%
Buy Reco %
75.00
75.00
Novo Nordisk A/S
NVO
Novo Nordisk A/S
P/E Ratio
9.89
9.89
1Y Return
16.83%
16.83%
Buy Reco %
21.42
21.42
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -4.40% growth, versus a trailing 3-year CAGR of 23.06%.

2026
Current$161.93Baseline
Analyst Target - 1 year
Target$154.8-4.4%

All values in $

202220232024202520262027$96.03$123.40$150.76Target-4.4%
2026
Current$161.93Baseline
Analyst Target - 1 year
Target$154.8-4.4%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 4.69% growth, versus a trailing 3-year CAGR of 8.04%.

2025
Current$54.81Baseline
Forecast for Dec 2026
High$58.71+7.13%
Average$57.38+4.69%
Low$56.12+2.4%

All values in $ Billion

20212022202320242025202643.9743.4646.6651.7254.81Low+2.4%Average+4.69%High+7.13%
2025
Current$54.81Baseline
Forecast for Dec 2026
High$58.71+7.13%
Average$57.38+4.69%
Low$56.12+2.4%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 2.01% growth, versus a trailing 3-year CAGR of 13.63%.

2025
Current$8.98Baseline
Forecast for Dec 2026
High$9.38+4.45%
Average$9.16+2.01%
Low$9.01+0.33%

All values in $

2021202220232024202520266.296.126.817.818.98Low+0.33%Average+2.01%High+4.45%
2025
Current$8.98Baseline
Forecast for Dec 2026
High$9.38+4.45%
Average$9.16+2.01%
Low$9.01+0.33%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

13.3
2.4
13.5
3.1
14.4
3.2
15
1.2
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue12.8713.1713.5513.6214.8314.3513.3313.5214.4115.02
Net Income3.243.182.813.604.043.922.403.153.261.20
Net Profit Margin25.21%24.21%20.78%26.47%27.23%27.35%18.06%23.33%22.65%7.99%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Novartis AG ADR 30.398.193.85
Eli Lilly and Company45.7831.351.35
Johnson & Johnson40.397.983.04
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare NVS with any stock or ETF
Compare NVS with any stock or ETF
Comparing from
NVS
LLY
JNJ
Loading...

Frequently asked questions

  1. Novartis AG ADR (NVS) share price today is $161.91 as of November 6, 2026 at 2:29 AM IST. The stock touched a day high of $165.94 and a day low of $161.68.

  2. Novartis AG ADR stock trades on NYSE under the ticker symbol NVS.

  3. Novartis AG ADR's market capitalization is $300.78B as of November 6, 2026 at 2:29 AM IST.

  4. Novartis AG ADR's price-to-earnings (P/E) ratio is 30.39 as of November 5, 2026.

  5. Novartis AG ADR's price-to-book (P/B) ratio is 8.19 as of November 5, 2026.

  6. Yes, Novartis AG ADR pays a dividend, with a current dividend yield of 2.98%.

  7. Yes, You can buy Novartis AG ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Novartis AG ADR shares in three steps: 1. Search Novartis AG ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Novartis AG ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Novartis AG ADR (NVS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0617 shares at the current price of $161.91.

Loading...